bdc – -Translation – Keybot Dictionary

Show text Show cached source Open source URL	Accel-Rx et BDC Capital s'allient pour favoriser la croissance des entreprises en sciences de la vie
Compare text pages Compare HTM pages Open source URL Open target URL Define rce-nce.gc.ca as primary domain	Accel-Rx and BDC partnership to grow life sciences companies

Show text Show cached source Open source URL	Accel-Rx and BDC Capital Invest in KisoJi Biotechnology (disponible en anglais seulement)
Compare text pages Compare HTM pages Open source URL Open target URL Define rce-nce.gc.ca as primary domain	Accel-Rx and BDC Capital Invest in KisoJi Biotechnology

Show text Show cached source Open source URL	Accueil > Retombées de l'innovation > Articles percutants > Accel-Rx et BDC Capital sallient pour favoriser la croissance des entreprises en sciences de la vie
Compare text pages Compare HTM pages Open source URL Open target URL Define rce-nce.gc.ca as primary domain	Home > Innovation Impacts > Impact stories > Accel-Rx and BDC partnership to grow life sciences companies

Les entreprises retenues reçoivent du financement de démarrage pouvant atteindre 1 million de dollars qui sera égalé par dautres investisseurs dAccel-Rx et du partenaire de financement BDC Capital ainsi que des services de soutien pour quelles deviennent des entreprises prêtes pour un investissement de série A.

Compare text pages Compare HTM pages Open source URL Open target URL Define rce-nce.gc.ca as primary domain

Accel-Rx leverages the expertise and infrastructure already created at seven CECRs (the Centre for Drug Research and Development [CDRD], MaRS Innovation, the Vancouver Prostate Centres Translational Research Initiative for Accelerated Discovery and Development, the Centre for Commercialization of Regenerative Medicine, the Centre for Probe Development and Commercialization, NEOMED and the MedDev Commercialization Centre) to aid in identifying technologies from across the country. Accel-Rx then employs a highly-qualified and diverse panel of experts to aid in the further screening and evaluation of these opportunities in order to select the top 3-4 companies per year with the highest technical and commercial potential to become part of the Accel-Rx Growth Platform. The selected companies receive an investment of up to $1 million in seed funding from Accel-Rx and funding partner BDC Capital to be matched by other investors as well as support services to ensure their development into Series A investment ready companies.

AccelRx_fra

Le Canada a trouvé un nouveau moyen pour que son investissement de 6 milliards de dollars dans la recherche fondamentale en santé se transforme en entreprises prospères et bien gérées. Le centre AccelRx établira un partenariat avec BDC Capital pour investir chaque année jusqu'à 1 million de dollars dans trois ou quatre entreprises du secteur des sciences de la vie.

Compare text pages Compare HTM pages Open source URL Open target URL Define rce-nce.gc.ca as primary domain

Canada has a new way to turn the country’s $6-billion investment in basic health research into successful and well-managed companies. Accel-Rx will partner with BDC Capital to invest up to $1,000,000—matched by other investors—in three to four life sciences companies annually. Five health‑related CECRs representing 70% of the country’s drug development pipeline will share their most commercially promising discoveries with Accel-Rx. The new CECR will make them investment-ready by providing entrepreneurial training and access to capital, specialized infrastructure, strategic partners and experienced entrepreneurs.

MaRS Innovation repense...

En février 2016, Accel-Rx Health Sciences Accelerator, BDC Capital, MI et d'autres partenaires ont investi 2 millions de dollars dans ScarX Therapeutics, entreprise issue d'une découverte de MI et du Hospital for Sick Children de Toronto qui commercialise une crème topique disponible sur ordonnance.

Compare text pages Compare HTM pages Open source URL Open target URL Define rce-nce.gc.ca as primary domain

In February, Accel-Rx, BDC Capital, MI and other partners invested $2 million in ScarX Therapeutics, a spin-off of MI and Toronto's Hospital for Sick Children that is commercializing a topical prescription cream developed by orthopedic surgeon Benjamin Alman. The cream promises to treat and prevent scars following surgery. The investment will allow ScarX to complete a Phase 1 clinical trial of its lead candidate, SCX-001 and position the company for Series A financing.

Accel-Rx et BDC Capital ont participé à un investissement de démarrage de 5 millions de dollars pour SoundBite Medical, qui a obtenu du financement extérieur de Bertrand Group et de divers investisseurs providentiels.

Compare text pages Compare HTM pages Open source URL Open target URL Define rce-nce.gc.ca as primary domain

Accel-Rx and BDC Capital participated in a $5 million seed investment round for SoundBite Medical, with external funding coming from the Bertrand Group and various angel investors. SoundBite has developed a novel, first-in-class, crossing guidewire to deliver shockwaves for interventional cardiology applications. This investment will support commercialization and clinical validation of their technology, with a Phase 1 clinical trial planned for early 2017.

MaRS Innovation repense...

En outre, MI obtient le financement et l'appui d'autres centres de commercialisation et accélérateurs, y compris trois CECR qu'il a aidé à établir : le Centre pour la commercialisation de la médecine régénératrice, le Centre for Commercialization of Antibodies and Biologics et Accel-Rx Health Sciences Accelerator, partenariat entre cinq CECR et BDC Capital qui offre jusqu'à 500 000 dollars en financement de démarrage.

Compare text pages Compare HTM pages Open source URL Open target URL Define rce-nce.gc.ca as primary domain

In addition, MI leverages funding and support from other commercialization centres and accelerators, including three CECRs it helped found: the Centre for Commercialization of Regenerative Medicine (CCRM), the Centre for the Commercialization of Antibodies and Biologics (CCAB) and the Accel-Rx Health Sciences Accelerator, a partnership between five CECRs and BDC Capital that provides up to $500,000 in seed capital.

« Un des principaux éléments qui nous ont attirés vers Accel-Rx est le fait qu'il s'agit d'une collaboration pancanadienne qui exploite les forces des centres de commercialisation déjà en place, affirme le vice-président, Investissements stratégiques et partenariats, de BDC Capital, Dominique Bélanger. Il ne s'agit pas ici d'une seule université qui mène un projet en vase clos. Cet atout accroît réellement nos chances de succès. »

Compare text pages Compare HTM pages Open source URL Open target URL Define rce-nce.gc.ca as primary domain

"A key element that pulled us towards Accel-Rx is the fact that it's a pan-Canadian collaboration utilizing strengths in existing commercialization centres. It's not just one university doing something on its own in a silo. That strength really increases our chances of success," says Dominique Bélanger, VP, Strategic Investments and Partnerships at BDC Capital.

Show text Show cached source Open source URL	Accel-Rx et BDC Capital, ainsi que le Fonds de solidarité FTQ et Lumira Capital, ont investi 4 millions de dollars dans KisoJi Biotechnology, une entreprise qui met au point un anticorps du récepteur de la dopamine qui régit la différenciation des cellules souches du cancer.
Compare text pages Compare HTM pages Open source URL Open target URL Define rce-nce.gc.ca as primary domain	Accel-Rx and BDC Capital, along with Fonds de solidarité FTQ and Lumira Capital, invested $4 million in KisoJi Biotechnology, a company developing dopamine receptor antibodies that drive cancer stem cell differentiation. This investment will allow Kisoji to obtain proof of concept data, determine a lead candidate and potentially begin a Phase 1 clinical trial by 2018.

AccelRx_fra

BDC Capital appuie maintenant les premières étapes de la création d'entreprises dans le domaine des sciences de la vie partout au Canada. CDRD Ventures Inc. et les CECR qui sont réunis dans AccelRx sont bien placés pour aider le secteur des soins de santé.

Compare text pages Compare HTM pages Open source URL Open target URL Define rce-nce.gc.ca as primary domain

BDC Capital now supports early-stage health sciences company creation across Canada. CDRD Ventures Inc. and the consortium of CECRs they have pulled together under the Accel-Rx framework are uniquely positioned to support the healthcare space. This pan-Canadian collaboration really increases success chances for the companies involved in the program.Dominique Bélanger, VP, Strategic Investments and Partnerships, BDC Capital

AccelRx_fra

Compare text pages Compare HTM pages Open source URL Open target URL Define rce-nce.gc.ca as primary domain

Show text Show cached source Open source URL	Le groupe Investissements stratégiques et partenariats de BDC Capital appuie de nombreux accélérateurs dans divers secteurs, mais le partenariat avec Accel-Rx est le premier en sciences de la vie. Or, le secteur se caractérise par les défis inhérents que sont le long cycle de vie des produits, le besoin d'infrastructure imposante et le grand besoin de capitaux.
Compare text pages Compare HTM pages Open source URL Open target URL Define rce-nce.gc.ca as primary domain	BDC's Strategic Investments & Partnerships team supports many accelerators in a variety of sectors, but this partnership with Accel-Rx signals its first in the health sciences, a sector with inherent challenges including long product cycles, heavy infrastructure needs and high capital requirements.

Les technologies et les entreprises ayant un bon potentiel commercial seront gérées avec rigueur et diligence et, chaque année, les trois ou quatre plus prometteuses d'entre elles recevront de BDC Capital et d'Accel-Rx un financement sous forme de dette convertible pouvant atteindre 1 million de dollars, qui sera égalé par d'autres investisseurs.

Compare text pages Compare HTM pages Open source URL Open target URL Define rce-nce.gc.ca as primary domain

Commercially-promising technologies and companies will be subject to rigorous due diligence, with three to four of the most promising ones selected each year to receive up to $1,000,000 in convertible debt funding from BDC Capital and Accel-Rx to be matched by other investors. Convertible debt is like a debenture that can be repaid or converted into equity, giving companies time to further develop their business and attract series A venture capital funding.

Show text Show cached source Open source URL	Accel-Rx Completes First Investment in Early Stage Company, Encycle Therapeutics, in partnership with BDC Capital (disponible en anglais seulement)
Compare text pages Compare HTM pages Open source URL Open target URL Define rce-nce.gc.ca as primary domain	Accel-Rx Completes First Investment in Early Stage Company, Encycle Therapeutics, in partnership with BDC Capital

Show text Show cached source Open source URL	Accel-Rx and BDC Capital Invest in Medical Technology Company, SoundBite Medical Solutions (disponible en anglais seulement)
Compare text pages Compare HTM pages Open source URL Open target URL Define rce-nce.gc.ca as primary domain	Accel-Rx and BDC Capital Invest in Medical Technology Company, SoundBite Medical Solutions

Centre for Drug Researc...

Show text Show cached source Open source URL	Accel-Rx Health Sciences Accelerator to Partner with BDC Venture Capital to Help Create up to 20 Leading Canadian Companies (disponible en anglais seulement)
Compare text pages Compare HTM pages Open source URL Open target URL Define rce-nce.gc.ca as primary domain	Accel-Rx Health Sciences Accelerator to Partner with BDC Venture Capital to Help Create up to 20 Leading Canadian Companies

Show text Show cached source Open source URL	Accel-Rx et BDC Capital sallient pour favoriser la croissance des entreprises en sciences de la vie
Compare text pages Compare HTM pages Open source URL Open target URL Define rce-nce.gc.ca as primary domain	Accel-Rx and BDC partnership to grow life sciences companies

Show text Show cached source Open source URL	Accel-Rx and BDC Capital invest in ImStar Therapeutics, a Canadian company developing therapeutics to treat ALS (disponible en anglais seulement)
Compare text pages Compare HTM pages Open source URL Open target URL Define rce-nce.gc.ca as primary domain	Accel-Rx and BDC Capital invest in ImStar Therapeutics, a Canadian company developing therapeutics to treat ALS